Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry

被引：0

作者：

Hernando Cubero, J. ^{[1
]}

Lago, N. Martinez ^{[2
]}

Mitjavila, M. ^{[3
]}

Garcia-Burillo, A. ^{[4
]}

Pubul, V. ^{[5
]}

Bello, P. ^{[6
]}

Cano, J. M. ^{[7
]}

Llana, B. ^{[8
]}

Castellon, M. ^{[9
]}

Rodeno, E. ^{[10
]}

Pineiro, A. ^{[11
]}

Soldevilla, C. ^{[12
]}

Nevares, M. ^{[13
]}

Aller, J. ^{[14
]}

Anido Herranz, U. ^{[15
]}

Carnero Lopez, B. ^{[16
]}

Nogareda, Z. ^{[5
]}

Garcia Alvarez, A. ^{[17
]}

Jimenez Fonseca, P. ^{[18
]}

Capdevila Castillon, J. ^{[19
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Hosp Arquitecto Marcide, CHUF Complejo Hosp Univ Ferrol, Med Oncol, Ferrol, Spain

[3] Hosp Univ Puerta Hierro, Nucl Med, Majadahonda, Spain

[4] Vall dHebron Univ Hosp, Nucl Med, Barcelona, Spain

[5] Complexo Hosp Univ Santiago Compostela, Nucl Med, Santiago De Compostela, Spain

[6] Hosp Univ & Politecn La Fe, Nucl Med, Valencia, Spain

[7] Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain

[8] Hosp Univ Cent Asturias, Nucl Med, Oviedo, Spain

[9] Hosp Clin Univ Virgen de la Arrixaca, Nucl Med, El Palmar, Spain

[10] Hosp Univ Cruces, Nucl Med, Baracaldo, Spain

[11] Hosp Univ Virgen de las Nieves, Nucl Med, Granada, Spain

[12] Hosp Santa Creu & Sant Pau, Nucl Med, Barcelona, Spain

[13] Hosp Univ Burgos, Nucl Med, Burgos, Spain

[14] Hosp Univ Puerta De Hierro, Endocrinol, Majadahonda, Spain

[15] CHUS Complejo Hosp Univ Santiago de Compostela SE, Med Oncol, La Coruna, Spain

[16] Hosp Univ Lucus Augusti, Med Oncol, Lugo, Spain

[17] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[18] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain

[19] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1157P

引用

页码：S756 / S756

页数：1

共 50 条

[41] Initial Experience With Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NETS) at a Tertiary Care United States Center
Heckert, Jason
Botterbusch, Samuel
Kipnis, Sarit
Bennet, Bonita
Creamer, Caroline
Alderson, Alice
Eads, Jennifer
Soulen, Michael
Pryma, Daniel
Mankoff, David
Metz, David
Katona, Bryson
PANCREAS, 2020, 49 (03) : 470 - 471
[42] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
Miotto, M.
Nessi, C.
Cingarlini, S.
Severi, S.
Paganelli, G.
Malleo, G.
D'Onofrio, M.
Pea, A.
Vincenzi, S.
Scarpa, A.
Salvia, R.
Landoni, L.
NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
[43] PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH METASTATIC NEUROENDOCRINE TUMORS: THE UNIVERSITY GENERAL HOSPITAL OF ATHENS "ATTIKON" PARADIGM
Liotsou, T.
Stefanoyiannis, A. P.
Chatziioannou, S. N.
ANTICANCER RESEARCH, 2014, 34 (10) : 6031 - 6031
[44] Systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
Teran Brage, E.
Campana-Diaz, E.
Navarro Martin, M.
Garcia-Talavera, P.
Lopez Gutierrez, A.
Reguera Puertas, P.
Rama-Alonso, S.
Roldan Ruiz, J.
Posado Dominguez, L.
Pablo Martin, E.
Lozano Mejorada, R.
Fonseca Sanchez, E.
ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
[45] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
Marco Schiavo Lena
Stefano Partelli
Paola Castelli
Valentina Andreasi
Chanel Elisha Smart
Eleonora Pisa
Mirco Bartolomei
Emilio Bertani
Giuseppe Zamboni
Massimo Falconi
Claudio Doglioni
Endocrine Pathology, 2020, 31 : 119 - 131
[46] Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors.
Chau, Justin
Yu, Nanmeng
Bakeri, Hirva
Menda, Yusuf
Dillon, Joseph S.
Chandrasekharan, Chandrikha
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[47] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
Alayli, Adam
Ngo, Hoang
Sikaria, Dhiraj
Ahmed, Altan
Salloum, Elias
Strosberg, Jonathan R.
Al-Toubah, Taymeyah E.
Kis, Bela
Haider, Mintallah
El-Haddad, Ghassan
CANCERS, 2024, 16 (15)
[48] Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Baum, Richard P.
Wang, Peipei
Jakobsson, Vivianne
Zhao, Tianzhi
Schuchardt, Christiane
Khong, Pek-Lan
Zhang, Jingjing
THERANOSTICS, 2024, 14 (01): : 133 - 142
[49] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
Schiavo Lena, Marco
Partelli, Stefano
Castelli, Paola
Andreasi, Valentina
Smart, Chanel Elisha
Pisa, Eleonora
Bartolomei, Mirco
Bertani, Emilio
Zamboni, Giuseppe
Falconi, Massimo
Doglioni, Claudio
ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
[50] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs) in a United States (US) Population
Katona, Bryson W.
Riff, Brian P.
Soulen, Michael C.
Pryma, Daniel A.
Bennett, Bonita J.
Wild, Damian
Nicolas, Guillaume
Teitelbaum, Ursina R.
Metz, David C.
GASTROENTEROLOGY, 2016, 150 (04) : S208 - S209

← 1 2 3 4 5 →